HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and raises the price target from $11 to $12.
July 27, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals' price target has been raised from $11 to $12 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Verrica Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100